Pomerantz Law Firm Launches Investigation into Valneva SE Claims Amidst Share Price Decline
On October 8, 2025, Pomerantz LLP announced its investigation into claims made on behalf of investors in Valneva SE, a biopharmaceutical company known for its innovative vaccine developments, trading under the ticker symbol VALN on NASDAQ. The firm seeks to ascertain whether Valneva, along with certain executives and directors, has been involved in any fraudulent activities pertaining to securities or unlawful business practices that may have adversely affected investors.
This investigation follows alarming reports stemming from the U.S. Centers for Disease Control and Prevention (CDC) regarding Valneva's chikungunya vaccine, IXCHIQ. The CDC had revealed they were looking into cases of serious neurological and cardiac events that occurred post-vaccination in patients aged 65 and older. This announcement triggered a sharp decline in Valneva's stock prices, which dropped by approximately 13.57%, closing at $6.75 per American Depositary Receipt (ADR) by February 28, 2025.
The situation worsened when the U.S. Food and Drug Administration (FDA) announced on August 22, 2025, that it had suspended the marketing application for IXCHIQ due to safety concerns. This announcement led to a further decline in Valneva's ADR price, which plunged 18.99%, settling at $9.43 per ADR by August 25, 2025. Such substantial dips in stock prices raised alarms among investors, prompting them to seek legal recourse through Pomerantz LLP.
Pomerantz LLP is recognized as one of the leading law firms in the realms of corporate, securities, and antitrust class action litigation. With a history spanning over 85 years, it is credited with pioneering securities class actions. The firm has consistently fought for the rights of investors who have encountered fraud, breaches of fiduciary duty, and other forms of corporate misconduct. Notably, Pomerantz has successfully recovered multimillion-dollar damages on behalf of class members, demonstrating their commitment to holding corporations accountable for their actions.
Investors affected by the recent developments are encouraged to reach out to Danielle Peyton at Pomerantz LLP by email or phone, as the firm aims to explore potential grounds for a class action lawsuit. The legal proceedings are important as they could establish not only the responsibility of Valneva's management but also protect shareholder interests during this tumultuous period.
The firm's investigation comes at a time of heightened scrutiny within the pharmaceutical industry, emphasizing the need for transparency and safety, especially regarding vaccines that impact public health. As the healthcare landscape evolves with ongoing advancements, it is crucial for the actors within this space to operate under stringent ethical standards and be held accountable for lapses in practice.
Investors who believe they have been harmed by Valneva's actions should remain vigilant and consider joining Pomerantz LLP’s efforts in holding the company accountable. This case may not only encapsulate immediate financial repercussions for Valneva but also broader implications on regulatory practices within the pharmaceutical industry moving forward. As stakeholders await more information and resolutions, it is evident that the coming months are critical for both Valneva and its investors.
This investigation follows alarming reports stemming from the U.S. Centers for Disease Control and Prevention (CDC) regarding Valneva's chikungunya vaccine, IXCHIQ. The CDC had revealed they were looking into cases of serious neurological and cardiac events that occurred post-vaccination in patients aged 65 and older. This announcement triggered a sharp decline in Valneva's stock prices, which dropped by approximately 13.57%, closing at $6.75 per American Depositary Receipt (ADR) by February 28, 2025.
The situation worsened when the U.S. Food and Drug Administration (FDA) announced on August 22, 2025, that it had suspended the marketing application for IXCHIQ due to safety concerns. This announcement led to a further decline in Valneva's ADR price, which plunged 18.99%, settling at $9.43 per ADR by August 25, 2025. Such substantial dips in stock prices raised alarms among investors, prompting them to seek legal recourse through Pomerantz LLP.
Pomerantz LLP is recognized as one of the leading law firms in the realms of corporate, securities, and antitrust class action litigation. With a history spanning over 85 years, it is credited with pioneering securities class actions. The firm has consistently fought for the rights of investors who have encountered fraud, breaches of fiduciary duty, and other forms of corporate misconduct. Notably, Pomerantz has successfully recovered multimillion-dollar damages on behalf of class members, demonstrating their commitment to holding corporations accountable for their actions.
Investors affected by the recent developments are encouraged to reach out to Danielle Peyton at Pomerantz LLP by email or phone, as the firm aims to explore potential grounds for a class action lawsuit. The legal proceedings are important as they could establish not only the responsibility of Valneva's management but also protect shareholder interests during this tumultuous period.
The firm's investigation comes at a time of heightened scrutiny within the pharmaceutical industry, emphasizing the need for transparency and safety, especially regarding vaccines that impact public health. As the healthcare landscape evolves with ongoing advancements, it is crucial for the actors within this space to operate under stringent ethical standards and be held accountable for lapses in practice.
Investors who believe they have been harmed by Valneva's actions should remain vigilant and consider joining Pomerantz LLP’s efforts in holding the company accountable. This case may not only encapsulate immediate financial repercussions for Valneva but also broader implications on regulatory practices within the pharmaceutical industry moving forward. As stakeholders await more information and resolutions, it is evident that the coming months are critical for both Valneva and its investors.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.